Key Highlights
- Mark D. Eisner, M.D., M.P.H., joins Vir Biotechnology as Executive VP and CMO.
- Dr. Eisner to report directly to CEO Marianne De Backer.
- Former CMO of Sonoma Biotherapeutics with extensive clinical development expertise.
- Experience includes senior roles at FibroGen and Genentech.
- Dr. Eisner’s deep immunology and infectious disease knowledge critical for Vir’s growth.
Source: Business Wire
Notable Quotes
- “We are delighted to welcome Mark, a seasoned and highly respected scientist, clinician, and leader, to Vir’s Executive Management Team. His exceptional leadership skills with late-stage clinical experience and deep knowledge of immunology and infectious disease will be critical to the next phase of Vir’s growth,” – Dr. Marianne De Backer, CEO at Vir Biotechnology
- “I am thrilled to be joining Vir at this critical time and am looking forward to working with the talented teams to advance our clinical development programs. Patients have always been my guiding compass, so I am excited to have this opportunity to help translate Vir’s groundbreaking science into advances for human health.” – Mark D. Eisner, Executive VP and CMO at Vir Biotechnology
SoHC's Take
The appointment of Dr. Mark D. Eisner as Executive Vice President and Chief Medical Officer at Vir Biotechnology marks a significant strategic move for the company. With his extensive background in clinical development and his deep expertise in immunology and infectious diseases, Dr. Eisner is poised to drive Vir’s ambitious clinical programs forward. His proven track record at renowned companies like Sonoma Biotherapeutics, FibroGen, and Genentech underscores his capability to lead complex clinical initiatives and secure regulatory milestones. This leadership addition is expected to accelerate Vir’s mission to deliver transformative medicines to patients with unmet medical needs.
